JP7494222B2 - ピリジン－３－イル誘導体 - Google Patents

ピリジン－３－イル誘導体 Download PDF

Info

Publication number
JP7494222B2
JP7494222B2 JP2021574814A JP2021574814A JP7494222B2 JP 7494222 B2 JP7494222 B2 JP 7494222B2 JP 2021574814 A JP2021574814 A JP 2021574814A JP 2021574814 A JP2021574814 A JP 2021574814A JP 7494222 B2 JP7494222 B2 JP 7494222B2
Authority
JP
Japan
Prior art keywords
alkylene
isopropylphenyl
chloro
methoxypyridin
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021574814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537177A5 (enExample
JP2022537177A (ja
Inventor
ボリ マーティン
ブロッチ クリスティーン
レスコップ シリル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2022537177A publication Critical patent/JP2022537177A/ja
Publication of JP2022537177A5 publication Critical patent/JP2022537177A5/ja
Application granted granted Critical
Publication of JP7494222B2 publication Critical patent/JP7494222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Debugging And Monitoring (AREA)
JP2021574814A 2019-06-18 2020-06-17 ピリジン－３－イル誘導体 Active JP7494222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2019065963 2019-06-18
EPPCT/EP2019/065963 2019-06-18
PCT/EP2020/066767 WO2020254408A1 (en) 2019-06-18 2020-06-17 Pyridin-3-yl derivatives

Publications (3)

Publication Number Publication Date
JP2022537177A JP2022537177A (ja) 2022-08-24
JP2022537177A5 JP2022537177A5 (enExample) 2023-06-22
JP7494222B2 true JP7494222B2 (ja) 2024-06-03

Family

ID=71105482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574814A Active JP7494222B2 (ja) 2019-06-18 2020-06-17 ピリジン－３－イル誘導体

Country Status (18)

Country Link
US (1) US12479820B2 (enExample)
EP (1) EP3986884B1 (enExample)
JP (1) JP7494222B2 (enExample)
KR (1) KR102786045B1 (enExample)
CN (1) CN114026082B (enExample)
AR (1) AR119162A1 (enExample)
AU (1) AU2020298014B2 (enExample)
BR (1) BR112021025236A2 (enExample)
CA (1) CA3143618A1 (enExample)
CL (1) CL2021003348A1 (enExample)
IL (1) IL288950B2 (enExample)
MA (1) MA56504A (enExample)
MX (1) MX2021015727A (enExample)
PH (1) PH12021553178A1 (enExample)
SG (1) SG11202111162PA (enExample)
TW (1) TWI845708B (enExample)
UA (1) UA130692C2 (enExample)
WO (1) WO2020254408A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504415A (ja) * 2019-12-04 2023-02-03 イドーシア ファーマシューティカルズ リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061559T2 (hu) 2018-06-07 2023-07-28 Idorsia Pharmaceuticals Ltd Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ｕｂｅ株式会社 カルボキサミド化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512251A (ja) 2003-11-12 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド ４−フェニルピペリジンスルホニルグリシン輸送体インヒビター
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
JP2017500287A (ja) 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
WO2019234115A1 (en) 2018-06-07 2019-12-12 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (enExample) 1960-03-14
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005037269A1 (ja) 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
AU2008311971A1 (en) 2007-10-18 2009-04-23 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
EP2297153B1 (en) 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス， インコーポレイテッド 非全身性ｔｇｒ５アゴニスト
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512251A (ja) 2003-11-12 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド ４−フェニルピペリジンスルホニルグリシン輸送体インヒビター
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
JP2017500287A (ja) 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
WO2019234115A1 (en) 2018-06-07 2019-12-12 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504415A (ja) * 2019-12-04 2023-02-03 イドーシア ファーマシューティカルズ リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤

Also Published As

Publication number Publication date
WO2020254408A1 (en) 2020-12-24
EP3986884A1 (en) 2022-04-27
IL288950A (en) 2022-02-01
IL288950B2 (en) 2025-03-01
CN114026082A (zh) 2022-02-08
AR119162A1 (es) 2021-12-01
AU2020298014B2 (en) 2026-02-05
CA3143618A1 (en) 2020-12-24
US20220251068A1 (en) 2022-08-11
TWI845708B (zh) 2024-06-21
MA56504A (fr) 2022-04-27
CL2021003348A1 (es) 2022-09-23
KR102786045B1 (ko) 2025-03-24
JP2022537177A (ja) 2022-08-24
EP3986884B1 (en) 2026-07-08
US12479820B2 (en) 2025-11-25
BR112021025236A2 (pt) 2022-02-01
AU2020298014A1 (en) 2022-02-10
IL288950B1 (en) 2024-11-01
CN114026082B (zh) 2024-06-07
UA130692C2 (uk) 2026-04-22
PH12021553178A1 (en) 2022-11-07
MX2021015727A (es) 2022-01-24
KR20220020921A (ko) 2022-02-21
SG11202111162PA (en) 2021-11-29
TW202115011A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
TWI895300B (zh) 吖丁啶lpa1受體拮抗劑與抗纖維化藥劑之組合
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
JP7612669B2 (ja) アルファ－ｄ－ガラクトピラノシド誘導体
JP2010526145A (ja) ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
MX2011008308A (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica.
JP7386183B2 (ja) Ｌｐａ１受容体アンタゴニストとしてのアルコキシ置換ピリジニル誘導体及び繊維症の治療におけるその使用
TW202045498A (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
KR102786045B1 (ko) 피리딘-3-일 유도체
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
AU2016323254B2 (en) Non-steroidal glucocorticoid receptor modulators for local drug delivery
HK40066271A (en) Pyridin-3-yl derivatives
HK40066271B (en) Pyridin-3-yl derivatives
EA047605B1 (ru) Пиридин-3-ильные производные
EA040901B1 (ru) Алкокси-замещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240522

R150 Certificate of patent or registration of utility model

Ref document number: 7494222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150